The CEO and creator of Viking Therapeutics, Brian Lian, is at the core of the tale of how a Wall Street analyst created a $4 billion obesity medication company. His experience demonstrates how timing, scientific understanding, and financial know-how in a rapidly expanding healthcare industry may result in a billion-dollar biotech firm.
Brian Lian studied small and mid-size biotechnology companies for almost ten years as a Wall Street equities analyst before to starting his own business. Analyzing pharmaceutical companies creating remedies for conditions like diabetes and metabolic problems was part of his work.
His career path was altered in 2012 after he met with executives in the pharmaceutical industry. He discovered during that discussion that a business had lately purchased a number of diabetes medication candidates and was prepared to grant licenses for them. Lian decided to leave Wall Street and start his own biotech company to develop those medications rather than merely assess investment opportunities.
Viking Therapeutics’ launch Lian used a daring approach to start Viking Therapeutics Prospective early-stage drug candidates should be licensed.
Create therapies targeted at metabolic disorders, such as fatty liver disease and obesity.
Also Read:
Omar Khan: Aligning Legal Strategies with Business Growth
Gaurav Sharma: Building Trenity Consultants as a Trusted Partner in The Immigration Landscape
